Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nuvigil Labeling Will Likely Include Safety Information From Sparlon Clinical Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Cephalon’s follow-on product gets “approvable” letter as FDA considers common labeling for Provigil, Sparlon and Nuvigil.

You may also be interested in...



Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On

Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.

Nuvigil Draft Label Warning Includes Both Modafinil And Its Follow-On

Cephalon’s follow-on to the sleep disorder agent Provigil could be on the market by summer, despite “approvable” letter announced March 30.

Sparlon User Fee Date Extended To August

FDA has extended the user fee date for Cephalon's attention deficit/hyperactivity disorder treatment Sparlon (modafinil) to Aug. 22, the company said April 24

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel